Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
NetraMark Holdings ( (TSE:AIAI) ) has shared an update.
NetraMark Holdings Inc. has partnered with Pentara Corporation to launch a novel AI-driven site intelligence tool aimed at enhancing clinical trial integrity through advanced anomaly detection. This collaboration is expected to improve trial design by identifying potential data integrity issues early, thereby enhancing confidence in efficacy outcomes and optimizing future trials. The partnership marks a significant milestone for NetraMark, expanding its AI technology applications in clinical trials and providing Pentara with scalable monitoring solutions and real-time alerts.
More about NetraMark Holdings
NetraMark is a leader in developing Generative Artificial Intelligence (Gen AI) and Machine Learning (ML) solutions for the pharmaceutical industry. Its innovative algorithms allow for intelligent data transformation, enabling accurate disease segmentation and patient classification for drug sensitivity and treatment efficacy. Pentara provides statistical and data analysis services to the pharmaceutical and biotechnology industries, focusing on innovative solutions to improve drug development outcomes.
Average Trading Volume: 56,219
Technical Sentiment Signal: Buy
Current Market Cap: C$109.5M
For an in-depth examination of AIAI stock, go to TipRanks’ Overview page.